Associated Papers
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Wolf J et al.
Esmo Open, 2022
Case report: 16-yr life history and genomic evolution of an ER+ HER2- breast cancer.
Xu B et al.
Cold Spring Harbor Molecular Case Studies, 2020
33008833 (PubMed )
Supplement: supp_mcs.a005629_Supplemental_Files_1-5.pdf
Characterization of colibactin-associated mutational signature in an Asian oral squamous cell carcinoma and in other mucosal tumor types.
Boot A et al.
Genome Research, 2020
32661091 (PubMed )
Supplement: supp_gr.255620.119_Supplemental_Table_S2.xlsx › Sheet1
Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response.
Qin J et al.
Translational Cancer Research, 2019
GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J et al.
Lung Cancer (amsterdam, Netherlands), 2018
Select a paper to view details